Status:
COMPLETED
Retrospective and Prospective Disease Progression and Quality of Life in XLH
Lead Sponsor:
Medialis Ltd.
Conditions:
X-linked Hypophosphatemia (XLH)
Eligibility:
All Genders
28+ years
Brief Summary
There is limited empirical data documenting disease progression and impact on quality of life for patients with X-linked hypophosphatemia (XLH). This study seeks to investigate the impact of XLH in ad...
Eligibility Criteria
Inclusion
- • Participant has a diagnosis of XLH
- Participant is aged 28 years and above.
- Participant is capable of providing informed consent
- Participant is able to read and converse in English
- Participant is able to comply with the study schedule (5 tele-visits over a 12-month period)
Exclusion
- • Participant does not have a diagnosis of XLH
- Participant is aged under 28 years
- Participant is not capable of giving informed consent
- Participant is unable to read and converse in English
- Participant is unable to comply the with study schedule (5 tele-visits over a 12-month period)
Key Trial Info
Start Date :
July 7 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 28 2021
Estimated Enrollment :
11 Patients enrolled
Trial Details
Trial ID
NCT04049877
Start Date
July 7 2019
End Date
July 28 2021
Last Update
October 23 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medialis
Oxford, United Kingdom, OX16 0AH